| Make foodmate.com your Homepage | Wap | Archiver
Advanced Top
Search Promotion
Search Promotion
Post New Products
Post New Products
Business Center
Business Center
 
Current Position:Home » News » Beverages & Alcohol » Beverages » Topic

Suntory closing in on deal to buy GSK's Lucozade and Ribena drinks brands

Zoom in font  Zoom out font Published: 2013-09-06  Origin: Reuters  Views: 32
Core Tip: Japan's Suntory Beverage & Food (2587.T) is in advanced talks to buy GlaxoSmithKline's (GSK.L) Lucozade and Ribena drinks for more than 1 billion pounds ($1.6 billion), in a deal that would pre-empt an auction of the brands.
Lucozade and Ribena

Japan's Suntory Beverage & Food (2587.T) is in advanced talks to buy GlaxoSmithKline's (GSK.L) Lucozade and Ribena drinks for more than 1 billion pounds ($1.6 billion), in a deal that would pre-empt an auction of the brands, two people close to the process said.

A deal could be announced in the next few days, one of the sources said on Thursday.

GlaxoSmithKline (GSK) - Britain's biggest drugmaker - announced plans in April to sell Lucozade and Ribena, which are big sellers in Britain but lack global reach, as the company seeks to make its consumer health business more focused.

JP Morgan (JPM.N) and Greenhill (GHL.N) are acting for GSK on the disposal.

The sale had been expected to attract interest from drinks companies and private equity houses, although Suntory was early on seen as a likely front-runner given its desire to build up its European drinks business after buying Orangina Schweppes for more than 300 billion yen ($3.0 billion) in 2009.

Officials at GSK and Suntory declined to comment on the situation.

Lucozade and Ribena have annual sales of just over 500 million pounds a year and industry analysts have been expecting a buyer to pay around two times sales.

A decision to sell the businesses directly to Suntory, bypassing a formal auction, would be a blow for private equity houses and other possible trade buyers that had also been lining up potential bids.

The strong cash flows offered by the two soft drinks had been expected to attract private equity houses such as Blackstone (BX.N), Lion Capital, Cinven CINV.UL, CVC Capital Partners CVC.UL and KKR (KKR.N). All have declined to comment.

Lucozade and Ribena no longer fit well in GSK's portfolio, since the company is focusing its consumer health operations increasingly on emerging markets, where both brands are relatively weak.

Both are veteran products - Lucozade was launched in 1927 and Ribena introduced 10 years later - yet they remain popular in Britain where they command a prominent position in retail outlets.

Ribena, in particular, is anchored firmly in its home market, both in terms of demand and supply. Around 90 percent of all the blackcurrants farmed in Britain and Ireland end up in the famous purple drink.
 
 
[ News search ]  [ ]  [ Notify friends ]  [ Print ]  [ Close ]

 
 
0 in all [view all]  Related Comments

 
Hot Graphics
Hot News
Hot Topics
 
 
Powered by Global FoodMate
Message Center(0)